Incidence of oral candidiasis during therapy with triamcinolone acetonide aerosol.
During treatment of 63 asthmatic patients for up to 12 months with an investigational drug, triamcinolone acetonide aerosol, no clinically diagnosed oral candidiasis occurred. After 14 months of treatment one patient (1.6%) developed an oral fungal infection. This low incidence prompted a survey concerning the incidence of oral candidal infection in the patients who took part in the entire clinical trial program of triamcinolone acetonide aerosol. The survey revealed a 2.5% occurrence of oral candidiasis among 674 patients who completed at least four weeks of treatment. While direct comparisons were not available, the incidence of oral candidiasis during treatment with triamcinolone acetonide aerosol was lower than that reported for other similarly administered steroid drugs.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D002177:Candidiasis / Q000139:chemically induced*; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced*; D014222:Triamcinolone Acetonide / Q000009:adverse effects* / Q000627:therapeutic use
D000336:Aerosols; D014222:Triamcinolone Acetonide